Evolus Inc (EOLS NASDAQ) stock market data APIs
$4.4325
0.11(2.5%)
as of February 5, 2026
Try our APIs with
free plan!
Evolus Inc Financial Data Overview
Price chart is built with
Anychart
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Prev. Close
4.4325
Open
4.5439
High
4.7122
Low
4.4086
52 wk Range
4.405-17.12
Market Cap
286 M
Shares Outstanding
64 820 K
Revenue
286 M
EPS
-0.24
Beta
1.011
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Evolus Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evolus Inc data using free add-ons & libraries
Get Evolus Inc Fundamental Data
Evolus Inc Fundamental data includes:
- Net Revenue: 286 M
- EBITDA: -31 432 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evolus Inc News
New
Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.7 per share a year ago. These figur...
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table
Key Points Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period...
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Key Points Oregon-based Stonepine Capital Management sold all 38,597 shares of its ANI Pharmaceuticals shares in the third quarter. The shares were worth about $2.52 million. The move marked a full e...
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026. On December 2, Mizuho lowered the firm’s price target on Evolus to $19 from $20, while keeping an Outperform rating on the sh...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
